Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Engineering a Two‐Component Hemostat for the Treatment of Internal Bleeding through Wound‐Targeted Crosslinking

Engineering a Two‐Component Hemostat for the Treatment of Internal Bleeding through Wound‐Targeted Crosslinking

Thumbnail Image
Download
Name

Adv Healthcare Materials - 2023 - Hong - Engineering a Two‐Component Hemostat for the Treatment of Internal Bleeding.pdf

Description
Published version
Size

4.48 MB

Format

Adobe PDF

Checksum (MD5)

477e62563ceb4692213550e08fd290a5

sword-2025-07-17T19:01:58.original.xml (130 B)
Original SWORD entry document
Author(s)
Hong, Celestine
•
He, Yanpu
•
Bowen, Porter A
•
Belcher, Angela M
•
Olsen, Bradley D
•
Hammond, Paula T
Date Issued
April 5, 2023
Journal
Advanced Healthcare Materials
Publisher
Wiley
Citation
Hong, Celestine, He, Yanpu, Bowen, Porter A, Belcher, Angela M, Olsen, Bradley D et al. 2023. "Engineering a Two‐Component Hemostat for the Treatment of Internal Bleeding through Wound‐Targeted Crosslinking." Advanced Healthcare Materials, 12 (20).
Version
Final published version
Abstract
Primary hemostasis (platelet plug formation) and secondary hemostasis (fibrin clot formation) are intertwined processes that occur upon vascular injury. Researchers have sought to target wounds by leveraging cues specific to these processes, such as using peptides that bind activated platelets or fibrin. While these materials have shown success in various injury models, they are commonly designed for the purpose of treating solely primary or secondary hemostasis. In this work, a two‐component system consisting of a targeting component (azide/GRGDS PEG‐PLGA nanoparticles) and a crosslinking component (multifunctional DBCO) is developed to treat internal bleeding. The system leverages increased injury accumulation to achieve crosslinking above a critical concentration, addressing both primary and secondary hemostasis by amplifying platelet recruitment and mitigating plasminolysis for greater clot stability. Nanoparticle aggregation is measured to validate concentration‐dependent crosslinking, while a 1:3 azide/GRGDS ratio is found to increase platelet recruitment, decrease clot degradation in hemodiluted environments, and decrease complement activation. Finally, this approach significantly increases survival relative to the particle‐only control in a liver resection model. In light of prior successes with the particle‐only system, these results emphasize the potential of this technology in aiding hemostasis and the importance of a holistic approach in engineering new treatments for hemorrhage.
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivatvies
https://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/160943
DOI of Published Version
https://doi.org/10.1002/adhm.202202756
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.